EP1131095A4 - Method of diagnosing, monitoring, staging, imaging and treating prostate cancer - Google Patents

Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

Info

Publication number
EP1131095A4
EP1131095A4 EP99955004A EP99955004A EP1131095A4 EP 1131095 A4 EP1131095 A4 EP 1131095A4 EP 99955004 A EP99955004 A EP 99955004A EP 99955004 A EP99955004 A EP 99955004A EP 1131095 A4 EP1131095 A4 EP 1131095A4
Authority
EP
European Patent Office
Prior art keywords
staging
diagnosing
imaging
monitoring
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99955004A
Other languages
German (de)
French (fr)
Other versions
EP1131095A1 (en
Inventor
Susana Salceda
Herve Recipon
Robert Cafferkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1131095A1 publication Critical patent/EP1131095A1/en
Publication of EP1131095A4 publication Critical patent/EP1131095A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP99955004A 1998-10-19 1999-10-19 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer Withdrawn EP1131095A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10473798P 1998-10-19 1998-10-19
US104737P 1998-10-19
PCT/US1999/024331 WO2000023111A1 (en) 1998-10-19 1999-10-19 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

Publications (2)

Publication Number Publication Date
EP1131095A1 EP1131095A1 (en) 2001-09-12
EP1131095A4 true EP1131095A4 (en) 2003-04-23

Family

ID=22302100

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99955004A Withdrawn EP1131095A4 (en) 1998-10-19 1999-10-19 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

Country Status (4)

Country Link
EP (1) EP1131095A4 (en)
JP (1) JP2002527758A (en)
CA (1) CA2347081A1 (en)
WO (1) WO2000023111A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
ATE429643T1 (en) * 2000-07-12 2009-05-15 Agensys Inc NEW TUMOR ANTIGEN THAT CAN BE USED FOR DIAGNOSIS AND THERAPY OF BLADDER, OVARY, LUNG AND KIDNEY CANCER
WO2002074907A2 (en) * 2001-02-02 2002-09-26 Bayer Pharmaceuticals Corporation Methods of modulating surfactant production
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US7893197B2 (en) 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
DE06814528T1 (en) 2005-09-12 2012-01-05 The Regent Of The University Of Michigan RECURRING GENUS FOR PROSTATE CANCER
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2007057119A2 (en) * 2005-11-15 2007-05-24 F. Hoffmann-La Roche Ag AZGP GENE SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs)
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
EP2171094B1 (en) 2007-07-06 2011-11-16 The Regents of the University of Michigan Mipol1-etv1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5800817B2 (en) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Recurrent gene fusion in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP4010456A4 (en) 2019-08-05 2023-09-13 Seer, Inc. Systems and methods for sample preparation, data generation, and protein corona analysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO1999067384A2 (en) * 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO1999067384A2 (en) * 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
AFAR DANIEL E H ET AL: "Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.", CANCER RESEARCH, vol. 61, no. 4, 15 February 2001 (2001-02-15), pages 1686 - 1692, XP002229964, ISSN: 0008-5472 *
BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 26, no. 4, 1 April 1995 (1995-04-01), pages 213 - 224, XP000611577, ISSN: 0270-4137 *
CHANG GLENN T G ET AL: "Differentially expressed genes in androgen-dependent and -independent prostate carcinomas", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 18, 1997, pages 4075 - 4081, XP002147425, ISSN: 0008-5472 *
DATABASE EMBL [online] 13 October 1997 (1997-10-13), XP002229965, retrieved from EMBL Database accession no. U75329 *
DATABASE EMBL [online] 16 May 2001 (2001-05-16), XP002229966, retrieved from EMBL Database accession no. AF329454 *
DATABASE EMBL [online] XP002220465, retrieved from EBI Database accession no. D14034 *
FRIEDRICH B ET AL: "DIFFERENTIATION-STAGE SPECIFIC EXPRESSION OF ONCOPROTEIN 18 IN HUMAN AND RAT PROSTATIC ADENOCARCINOMA", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 27, no. 2, 1995, pages 102 - 109, XP000938476, ISSN: 0270-4137 *
GAGNON S ET AL: "EXPRESSION OF ZINC ALPHA-2 GLYCOPROTEIN AND PSP-94 IN PROSTATIC ADENOCARCINOMA AN IMMUNOHISTOCHEMICAL STUDY OF 88 CASES", AMERICAN JOURNAL OF PATHOLOGY, vol. 136, no. 5, 1990, pages 1147 - 1152, XP001119271, ISSN: 0002-9440 *
HALE L P ET AL: "ZINC ALPHA-2-GLYCOPROTEIN IS EXPRESSED BY MALIGNANT PROSTATIC EPITHELIUM AND MAY SERVE AS A POTENTIAL SERUM MARKER FOR PROSTATE CANCER", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 7, no. 7, April 2001 (2001-04-01), pages 846 - 853, XP002951925, ISSN: 1078-0432 *
JACQUINET ERIC ET AL: "Cloning and characterization of the cDNA and gene for human epitheliasin.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 9, AF329454, May 2001 (2001-05-01), pages 2687 - 2699, XP002229963, ISSN: 0014-2956, Retrieved from the Internet <URL:EMBL> *
LIN B ET AL: "PROSTATE-LOCALIZED AND ANDROGEN-REGULATED EXPRESSION OF THE MEMBRANE-BOUND SERINE PROTEASE TMPRSS2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 1 September 1999 (1999-09-01), pages 4180 - 4184, XP000929801, ISSN: 0008-5472 *
LOPEZ-OTIN CARLOS ET AL: "Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features.", ENDOCRINE REVIEWS, vol. 19, no. 4, August 1998 (1998-08-01), pages 365 - 396, XP002220464, ISSN: 0163-769X *
OLSSON C A ET AL: "REVERSE TRANSCRIPTASE-POLYMER CHAIN REACTION ASSAYS FOR PROSTATE CANCER", UROLOGIC CLINICS OF NORTH AMERICA, SAUNDERS CO., LONDON, GB, vol. 24, no. 2, May 1997 (1997-05-01), XP002923009, ISSN: 0094-0143 *
PAOLONI-GIACOBINO A ET AL: "CLONING OF THE TMPRSS2 GENE, WHICH ENCODES A NOVEL SERINE PROTEASE WITH TRANSMEMBRANE, LDLRA, AND SRCR DOMAINS AND MAPS TO 21Q22.3", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 44, no. 3, U75329, 15 September 1997 (1997-09-15), pages 309 - 320, XP000856785, ISSN: 0888-7543, Retrieved from the Internet <URL:EMBL> *
See also references of WO0023111A1 *
UEYAMA HISAO ET AL: "Molecular cloning and chromosomal assignment of the gene for human Zn-alpha-2-glycoprotein.", BIOCHEMISTRY, vol. 32, no. 48, 1993, pages 12968 - 12976, XP002220728, ISSN: 0006-2960, Retrieved from the Internet <URL:EMBL> *

Also Published As

Publication number Publication date
JP2002527758A (en) 2002-08-27
EP1131095A1 (en) 2001-09-12
CA2347081A1 (en) 2000-04-27
WO2000023111A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
EP1239874A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1105528A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1131095A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001250932A8 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU6688598A (en) Method for diagnosing and staging prostate cancer
MXPA01008794A (en) Method of diagnosing and monitoring malignant breast carcinomas.
EP1117842A4 (en) Methods for selecting prostate cancer treatments and treating prostate cancer
AP2003002875A0 (en) Apparatus and method for treatment of water.
EP1090291A4 (en) Method for early diagnosis of, and determination of prognosis in, cancer
EP0975803A4 (en) Method for assessing prostate cancer
EP1082695A4 (en) Method and system for the computerized assessment of breast cancer risk
AU2001251013A1 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1082459A4 (en) A novel method of diagnosing, monitoring, and staging lung cancer
EP1267934A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1114679A4 (en) Method for producing soil, soil-treating unit, method for treating and unit for treating
AU2001251223A1 (en) Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
EP1107798A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1104486A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
AU4003597A (en) Methods of diagnosing and treating cancer
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1126877A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1082460A4 (en) A novel method of diagnosing, monitoring, and staging prostate cancer
AU2001271621A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001241656A1 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/395 A, 7A 61K 48/00 B, 7C 12P 19/34 B, 7C 12Q 1/68 B, 7G 01N 33/53 B, 7G 01N 33/574 B, 7G 01N 33/567 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030310

17Q First examination report despatched

Effective date: 20030616

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051206